 Seth Furgeson
Concepts (186)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ureteral Obstruction | 3 | 2021 | 64 | 1.290 |
Why?
| | Kidney | 6 | 2025 | 1511 | 1.170 |
Why?
| | Renal Insufficiency, Chronic | 5 | 2025 | 673 | 1.090 |
Why?
| | Group IV Phospholipases A2 | 2 | 2017 | 46 | 1.010 |
Why?
| | Myocytes, Smooth Muscle | 6 | 2018 | 274 | 0.880 |
Why?
| | Muscle, Smooth, Vascular | 6 | 2019 | 450 | 0.870 |
Why?
| | PTEN Phosphohydrolase | 7 | 2019 | 165 | 0.840 |
Why?
| | Renal Dialysis | 4 | 2026 | 467 | 0.820 |
Why?
| | Lipoxygenase Inhibitors | 2 | 2021 | 34 | 0.740 |
Why?
| | Kidney Failure, Chronic | 4 | 2026 | 600 | 0.710 |
Why?
| | Arachidonate 12-Lipoxygenase | 1 | 2021 | 17 | 0.700 |
Why?
| | Arachidonate 15-Lipoxygenase | 1 | 2021 | 20 | 0.700 |
Why?
| | Nephritis | 1 | 2021 | 22 | 0.690 |
Why?
| | Fibrosis | 7 | 2021 | 568 | 0.640 |
Why?
| | Inflammation Mediators | 2 | 2021 | 507 | 0.620 |
Why?
| | Kidney Tubules | 2 | 2019 | 118 | 0.590 |
Why?
| | Cell Dedifferentiation | 2 | 2016 | 32 | 0.560 |
Why?
| | Acidosis | 2 | 2025 | 107 | 0.550 |
Why?
| | Metabolome | 1 | 2021 | 391 | 0.540 |
Why?
| | Connective Tissue Growth Factor | 1 | 2017 | 29 | 0.520 |
Why?
| | Vascular Endothelial Growth Factor C | 1 | 2017 | 16 | 0.520 |
Why?
| | Polycystic Kidney Diseases | 3 | 2025 | 82 | 0.520 |
Why?
| | Nephrosclerosis | 1 | 2016 | 6 | 0.490 |
Why?
| | Kidney Diseases | 2 | 2017 | 428 | 0.490 |
Why?
| | Bone Marrow | 1 | 2017 | 310 | 0.470 |
Why?
| | Optical Imaging | 1 | 2016 | 63 | 0.470 |
Why?
| | Energy Metabolism | 1 | 2021 | 936 | 0.450 |
Why?
| | Cytokines | 2 | 2021 | 2086 | 0.440 |
Why?
| | Angiotensin II | 2 | 2019 | 102 | 0.440 |
Why?
| | Microscopy, Fluorescence | 1 | 2016 | 409 | 0.430 |
Why?
| | Retinoid X Receptors | 1 | 2014 | 42 | 0.420 |
Why?
| | Hypertension | 1 | 2022 | 1280 | 0.390 |
Why?
| | Uremia | 1 | 2013 | 15 | 0.380 |
Why?
| | Epithelial Cells | 2 | 2018 | 1141 | 0.330 |
Why?
| | Pseudohypoaldosteronism | 1 | 2010 | 2 | 0.330 |
Why?
| | Inflammation | 2 | 2014 | 2920 | 0.320 |
Why?
| | Tunica Intima | 2 | 2010 | 79 | 0.320 |
Why?
| | Carotid Artery Injuries | 1 | 2010 | 41 | 0.300 |
Why?
| | Gene Expression | 1 | 2014 | 1481 | 0.300 |
Why?
| | Mice, Knockout | 6 | 2025 | 3153 | 0.290 |
Why?
| | Peritonitis | 1 | 2009 | 83 | 0.280 |
Why?
| | Disease Models, Animal | 8 | 2025 | 4604 | 0.270 |
Why?
| | Cell Proliferation | 4 | 2016 | 2529 | 0.270 |
Why?
| | Drug Resistance, Bacterial | 1 | 2009 | 185 | 0.260 |
Why?
| | Peritoneal Dialysis | 1 | 2009 | 100 | 0.260 |
Why?
| | Community Health Workers | 2 | 2026 | 93 | 0.260 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 2 | 2023 | 244 | 0.260 |
Why?
| | Mice, Inbred C57BL | 5 | 2025 | 6041 | 0.250 |
Why?
| | Vascular Remodeling | 2 | 2019 | 209 | 0.240 |
Why?
| | Patient Navigation | 2 | 2026 | 130 | 0.240 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2008 | 252 | 0.240 |
Why?
| | Cognition | 2 | 2025 | 1286 | 0.230 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2025 | 456 | 0.230 |
Why?
| | Mice | 12 | 2025 | 18491 | 0.230 |
Why?
| | Animals | 16 | 2025 | 38410 | 0.230 |
Why?
| | Sodium Bicarbonate | 1 | 2025 | 48 | 0.220 |
Why?
| | Phenotype | 4 | 2021 | 3216 | 0.220 |
Why?
| | Lymphoid Tissue | 1 | 2025 | 81 | 0.210 |
Why?
| | Renal Insufficiency | 1 | 2025 | 172 | 0.200 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2024 | 149 | 0.190 |
Why?
| | Cerebrovascular Circulation | 1 | 2025 | 293 | 0.180 |
Why?
| | Self-Management | 1 | 2025 | 204 | 0.180 |
Why?
| | Chlorthalidone | 1 | 2022 | 3 | 0.180 |
Why?
| | Cognitive Dysfunction | 2 | 2025 | 479 | 0.180 |
Why?
| | Weight Gain | 1 | 2026 | 566 | 0.170 |
Why?
| | Signal Transduction | 6 | 2019 | 5272 | 0.170 |
Why?
| | Proto-Oncogene Proteins c-akt | 3 | 2014 | 440 | 0.170 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 94 | 0.160 |
Why?
| | Leukocytes | 1 | 2021 | 301 | 0.150 |
Why?
| | Nephrology | 1 | 2020 | 61 | 0.150 |
Why?
| | Cells, Cultured | 5 | 2019 | 4169 | 0.150 |
Why?
| | Chemokine CXCL12 | 2 | 2011 | 86 | 0.150 |
Why?
| | Receptors, Leukotriene | 1 | 2019 | 13 | 0.140 |
Why?
| | Rats | 5 | 2019 | 5613 | 0.140 |
Why?
| | Arachidonate 5-Lipoxygenase | 1 | 2019 | 37 | 0.140 |
Why?
| | Anti-Bacterial Agents | 1 | 2009 | 1940 | 0.140 |
Why?
| | Antihypertensive Agents | 1 | 2022 | 522 | 0.130 |
Why?
| | Lymphangiogenesis | 1 | 2017 | 27 | 0.130 |
Why?
| | Sepsis | 1 | 2024 | 671 | 0.130 |
Why?
| | Adaptive Immunity | 1 | 2018 | 171 | 0.130 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2010 | 459 | 0.130 |
Why?
| | Vascular Diseases | 1 | 2019 | 252 | 0.120 |
Why?
| | Arachidonic Acid | 1 | 2016 | 102 | 0.120 |
Why?
| | Humans | 17 | 2026 | 147293 | 0.120 |
Why?
| | Actins | 2 | 2018 | 428 | 0.120 |
Why?
| | Coronary Vessels | 1 | 2018 | 246 | 0.120 |
Why?
| | Dinoprostone | 1 | 2016 | 180 | 0.120 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2017 | 376 | 0.120 |
Why?
| | Acute Kidney Injury | 1 | 2024 | 880 | 0.110 |
Why?
| | Gene Silencing | 1 | 2016 | 203 | 0.110 |
Why?
| | Cardiovascular Diseases | 1 | 2008 | 2218 | 0.110 |
Why?
| | Male | 12 | 2026 | 73950 | 0.110 |
Why?
| | Cadherins | 1 | 2016 | 204 | 0.110 |
Why?
| | Cell Line | 2 | 2018 | 2832 | 0.100 |
Why?
| | Tetrahydronaphthalenes | 1 | 2014 | 34 | 0.100 |
Why?
| | Chemokine CCL2 | 1 | 2014 | 112 | 0.100 |
Why?
| | Atherosclerosis | 1 | 2018 | 411 | 0.100 |
Why?
| | Microfilament Proteins | 1 | 2014 | 135 | 0.100 |
Why?
| | Macrophages | 1 | 2021 | 1529 | 0.100 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2014 | 264 | 0.100 |
Why?
| | PPAR gamma | 1 | 2014 | 182 | 0.100 |
Why?
| | Calcium-Binding Proteins | 1 | 2014 | 222 | 0.090 |
Why?
| | MAP Kinase Signaling System | 1 | 2014 | 308 | 0.090 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2018 | 932 | 0.090 |
Why?
| | Heart-Assist Devices | 1 | 2018 | 571 | 0.090 |
Why?
| | Promoter Regions, Genetic | 1 | 2016 | 1253 | 0.090 |
Why?
| | Serum Response Factor | 1 | 2011 | 33 | 0.090 |
Why?
| | Neointima | 1 | 2011 | 18 | 0.080 |
Why?
| | WNK Lysine-Deficient Protein Kinase 1 | 1 | 2010 | 2 | 0.080 |
Why?
| | RNA Interference | 2 | 2010 | 477 | 0.080 |
Why?
| | Epithelial Sodium Channels | 1 | 2010 | 21 | 0.080 |
Why?
| | Phosphatidylinositol 3-Kinases | 2 | 2010 | 383 | 0.080 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2625 | 0.080 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2010 | 47 | 0.080 |
Why?
| | Potassium Channels | 1 | 2010 | 148 | 0.080 |
Why?
| | Virginiamycin | 1 | 2009 | 3 | 0.070 |
Why?
| | Internship and Residency | 1 | 2020 | 1279 | 0.070 |
Why?
| | Daptomycin | 1 | 2009 | 18 | 0.070 |
Why?
| | Oxazolidinones | 1 | 2009 | 16 | 0.070 |
Why?
| | Linezolid | 1 | 2009 | 25 | 0.070 |
Why?
| | Acetamides | 1 | 2009 | 42 | 0.070 |
Why?
| | Rats, Sprague-Dawley | 1 | 2014 | 2542 | 0.070 |
Why?
| | Autocrine Communication | 1 | 2008 | 38 | 0.070 |
Why?
| | Sympathetic Nervous System | 1 | 2008 | 181 | 0.060 |
Why?
| | NF-kappa B | 1 | 2010 | 676 | 0.060 |
Why?
| | Immunotherapy | 2 | 2018 | 672 | 0.060 |
Why?
| | Autophagy-Related Protein 7 | 1 | 2025 | 13 | 0.060 |
Why?
| | Hypoxia | 1 | 2013 | 1208 | 0.060 |
Why?
| | Regulatory-Associated Protein of mTOR | 1 | 2025 | 24 | 0.060 |
Why?
| | Colorado | 2 | 2026 | 4591 | 0.060 |
Why?
| | Middle Cerebral Artery | 1 | 2025 | 57 | 0.060 |
Why?
| | Ultrasonography, Doppler, Transcranial | 1 | 2025 | 48 | 0.060 |
Why?
| | MicroRNAs | 1 | 2011 | 694 | 0.050 |
Why?
| | Staphylococcus aureus | 1 | 2009 | 458 | 0.050 |
Why?
| | Staphylococcal Infections | 1 | 2009 | 395 | 0.050 |
Why?
| | Mutation | 2 | 2018 | 4130 | 0.050 |
Why?
| | Hypertension, Pulmonary | 2 | 2013 | 1977 | 0.050 |
Why?
| | Mice, Transgenic | 2 | 2019 | 2197 | 0.050 |
Why?
| | Stem Cells | 1 | 2008 | 630 | 0.050 |
Why?
| | B7-1 Antigen | 1 | 2023 | 55 | 0.050 |
Why?
| | Hyperplasia | 2 | 2018 | 177 | 0.050 |
Why?
| | Cell Movement | 1 | 2008 | 966 | 0.050 |
Why?
| | Mycobacterium bovis | 1 | 2003 | 15 | 0.050 |
Why?
| | BCG Vaccine | 1 | 2003 | 27 | 0.050 |
Why?
| | Female | 6 | 2026 | 80076 | 0.050 |
Why?
| | Mycobacterium Infections | 1 | 2003 | 55 | 0.050 |
Why?
| | Middle Aged | 5 | 2026 | 36821 | 0.040 |
Why?
| | Cell Differentiation | 3 | 2018 | 2054 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2023 | 246 | 0.040 |
Why?
| | Adult | 5 | 2026 | 41405 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2025 | 2080 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2023 | 1281 | 0.040 |
Why?
| | Aged | 4 | 2025 | 26514 | 0.040 |
Why?
| | Pilot Projects | 1 | 2025 | 1912 | 0.040 |
Why?
| | Neuropsychological Tests | 1 | 2024 | 1145 | 0.040 |
Why?
| | Prognosis | 1 | 2008 | 4383 | 0.040 |
Why?
| | Mice, Knockout, ApoE | 1 | 2018 | 11 | 0.030 |
Why?
| | TRPP Cation Channels | 1 | 2018 | 76 | 0.030 |
Why?
| | Career Choice | 1 | 2020 | 237 | 0.030 |
Why?
| | Disease Progression | 2 | 2018 | 2890 | 0.030 |
Why?
| | Qualitative Research | 1 | 2025 | 1735 | 0.030 |
Why?
| | Focus Groups | 1 | 2020 | 587 | 0.030 |
Why?
| | Blotting, Western | 1 | 2019 | 1186 | 0.030 |
Why?
| | Fellowships and Scholarships | 1 | 2020 | 357 | 0.030 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 200 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2019 | 1172 | 0.030 |
Why?
| | RNA | 1 | 2019 | 916 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2025 | 8430 | 0.020 |
Why?
| | Endothelium, Vascular | 1 | 2018 | 959 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2011 | 196 | 0.020 |
Why?
| | Models, Animal | 1 | 2011 | 394 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 2011 | 325 | 0.020 |
Why?
| | Receptors, CXCR4 | 1 | 2008 | 91 | 0.020 |
Why?
| | Hematopoietic Stem Cells | 1 | 2011 | 435 | 0.020 |
Why?
| | Arteries | 1 | 2008 | 262 | 0.010 |
Why?
| | United States | 1 | 2024 | 16313 | 0.010 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2008 | 300 | 0.010 |
Why?
| | RNA, Small Interfering | 1 | 2008 | 643 | 0.010 |
Why?
| | Up-Regulation | 1 | 2008 | 848 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2013 | 2973 | 0.010 |
Why?
| | Heart Failure | 1 | 2018 | 2334 | 0.010 |
Why?
| | Phosphorylation | 1 | 2008 | 1721 | 0.010 |
Why?
| | Hepatitis | 1 | 2003 | 43 | 0.010 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2003 | 71 | 0.010 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2003 | 261 | 0.010 |
Why?
| | Pneumonia | 1 | 2003 | 636 | 0.010 |
Why?
|
|
Furgeson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|